Picture Berlin Partner Top News EIC Accelerator Noah Labs MyoPax 650x100px

Document › Details

TME Pharma N.V.. (12/4/24). "Press Release: (CORRECTING and REPLACING) TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of T

	Organisation	TME Pharma N.V. (EuroNext Growth Paris: ALTME)
	Group	TME Pharma (Group)
	Organisation 2	EuroNext Growth Paris
	Group	Euronext (Group)
	Product	olaptesed pegol (NOX-A12)
	Product 2	emapticap pegol (NOX-E36)
	Person	Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)
	Person 2	van Renterghem, Guillaume (LifeSci 202106 Managing Director at LifeSci Advisors in Zurich)

Original Document
accessed by [iito] on 2025-02-01

Record changed: 2025-03-07

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for TME Pharma (Group)

[1] TME Pharma N.V.. (1/29/25). "Press Release: TME Pharma Announces Collaboration with Aimed Analytics for AI-Driven Drug Discovery and Optimization". Berlin....
[2] TME Pharma N.V.. (10/31/24). "Press Release: TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer". Berlin....
[3] TME Pharma N.V.. (9/30/24). "Press Release: TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board". Berlin....
[4] TME Pharma N.V.. (7/22/24). "Press Release: TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36". Berlin....
[5] TME Pharma N.V.. (6/18/24). "Press Release: TME Pharma Announces Results of Successful Capital Increase With €2.35 Million Raised". Berlin....
[6] TME Pharma N.V.. (4/23/24). "Press Release: TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer". Berlin....
[7] TME Pharma N.V.. (1/23/23). "Press Release: TME Pharma Provides Clinical Update on the GLORIA Expansion Arm Testing NOX-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma". Berlin....
[8] Noxxon Pharma N.V.. (1/3/22). "Press Release: Noxxon Secures €17 Million Expansion of Equity-linked Facility with Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs [ corrected version of press release originally issued 29 Dec 2021 ...
[9] Noxxon Pharma N.V.. (10/27/21). "Press Release: Experienced Financial Executive, Bryan Jennings, Joins Noxxon as CFO". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]